Lineage Cell Therapeutics, Inc. (LCTX) Debt Components
- 2020-06-30: Convertible Notes Payable, CurrentUSD (m); Notes Payable, CurrentUSD (m); Long-term Debt and Lease Obligation, CurrentUSD (m); Debt Instrument, Face AmountUSD $24.40M.
- 2019-03-31: Convertible Notes Payable, CurrentUSD (m); Notes Payable, CurrentUSD $18.00K; Long-term Debt and Lease Obligation, CurrentUSD (m); Debt Instrument, Face AmountUSD (m).
- 2018-12-31: Convertible Notes Payable, CurrentUSD (m); Notes Payable, CurrentUSD $70.00K; Long-term Debt and Lease Obligation, CurrentUSD (m); Debt Instrument, Face AmountUSD (m).
- 2018-09-30: Convertible Notes Payable, CurrentUSD (m); Notes Payable, CurrentUSD $70.00K; Long-term Debt and Lease Obligation, CurrentUSD (m); Debt Instrument, Face AmountUSD (m).
Lineage Cell Therapeutics, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Convertible Notes Payable, Current USD | Notes Payable, Current USD | Long-term Debt and Lease Obligation, Current USD | Debt Instrument, Face Amount USD | Debt Instrument, Convertible, Beneficial Conversion Feature USD | Debt Instrument, Increase, Accrued Interest USD | Notes Payable, Fair Value Disclosure USD |
|---|---|---|---|---|---|---|---|
| 2020-06-30 | (m) | (m) | (m) | $24.40M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $18.00K | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $70.00K | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $70.00K | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $120.00K | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $120.00K | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | 12 month · $304.00K | (m) | (m) |
| 2017-12-31 | (m) | $152.00K | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $13.00K | $126.00K | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $2.56M | $124.00K | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $1.07M | $124.00K | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | 12 month · $701.00K | (m) | (m) |
| 2016-12-31 | $833.00K | $99.00K | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $357.00K | $95.00K | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | 6 month · $-46.00K | (m) |
| 2016-06-30 | (m) | $95.00K | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $95.00K | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $0.00 | $95.00K | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | $26.00K | (m) | (m) | (m) | $363.00K |
| 2015-09-30 | $255.00K | $95.00K | $0.00 | (m) | (m) | (m) | $363.00K |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | 6 month · $-9.00K | (m) |
| 2015-06-30 | $238.00K | (m) | $3.00K | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $17.31K | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $0.00 | $31.00K | (m) | (m) | (m) | (m) |
| 2014-12-31 | $60.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $44.96K | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $57.50K | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | 12 month · $0.00 | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | 12 month · $0.00 | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | 12 month · $-304.40K | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |